[ET Net News Agency, 11 June 2021] Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
(02196) said its subsidiary Fosun Pharmaceutical Industrial has recently received the
approval for Investigational New Drug from the National Medical Products Administration of
consent to commence clinical trial of Balixafortide licensed to the group for use in
combination with Eribulin in the treatment of HER2 negative, locally recurrent or
metastatic breast cancer.
Fosun Pharmaceutical Industrial intends to conduct clinical trials of the
Investigational New Drug in the PRC (excluding Hong Kong and Macau SAR and Taiwan Region)
in due course as and when the conditions permitted. (RC)